CA2534120C - Medicaments for inhalation comprising anticholinergics and a betamimetic - Google Patents

Medicaments for inhalation comprising anticholinergics and a betamimetic Download PDF

Info

Publication number
CA2534120C
CA2534120C CA2534120A CA2534120A CA2534120C CA 2534120 C CA2534120 C CA 2534120C CA 2534120 A CA2534120 A CA 2534120A CA 2534120 A CA2534120 A CA 2534120A CA 2534120 C CA2534120 C CA 2534120C
Authority
CA
Canada
Prior art keywords
pharmaceutical combination
combination according
mol
methyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2534120A
Other languages
English (en)
French (fr)
Other versions
CA2534120A1 (en
Inventor
Christopher John Montague Meade
Michel Pairet
Michael P. Pieper
Ingo Konetzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2534120(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA2534120A1 publication Critical patent/CA2534120A1/en
Application granted granted Critical
Publication of CA2534120C publication Critical patent/CA2534120C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2534120A 2003-07-31 2004-07-17 Medicaments for inhalation comprising anticholinergics and a betamimetic Expired - Fee Related CA2534120C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03017349 2003-07-31
EP03017349.6 2003-07-31
PCT/EP2004/008013 WO2005013994A1 (en) 2003-07-31 2004-07-17 Medicaments for inhalation comprising anticholinergics and a betamimetic

Publications (2)

Publication Number Publication Date
CA2534120A1 CA2534120A1 (en) 2005-02-17
CA2534120C true CA2534120C (en) 2012-09-11

Family

ID=34130044

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2534120A Expired - Fee Related CA2534120C (en) 2003-07-31 2004-07-17 Medicaments for inhalation comprising anticholinergics and a betamimetic

Country Status (5)

Country Link
EP (1) EP1651224B1 (https=)
JP (1) JP2007500676A (https=)
AT (1) ATE526967T1 (https=)
CA (1) CA2534120C (https=)
WO (1) WO2005013994A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
DE102004038885A1 (de) * 2004-08-10 2006-02-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum
EP2484382A1 (en) * 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
CA2607101A1 (en) * 2005-05-04 2006-11-09 Boehringer Ingelheim International Gmbh Inhalation device containing plural doses of a pharmaceutical composition
EP1893203A2 (en) * 2005-05-31 2008-03-05 Boehringer Ingelheim International GmbH Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
CN101198313A (zh) * 2005-08-01 2008-06-11 奇斯药制品公司 通过喷雾施用的包含长效β2-激动剂的药物制剂
CL2008000500A1 (es) * 2007-02-19 2008-09-05 Cipla Ltd Combinacion farmaceutica que comprende una combinacion de dos o mas broncodilatadores o una combinacion de al menos un broncodilatador y al menos un corticosteroide; uso para tratar o prevenir una enfermedad respiratoria; e inhalador que comprende di
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
DE10050995A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10050994A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
DE10200943A1 (de) * 2002-01-12 2003-07-24 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Scopinestern
DE10203749A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203741A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203753A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP3384931B1 (en) * 2002-03-01 2019-07-24 Chiesi Farmaceutici S.p.A. Formoterol superfine formulation
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid

Also Published As

Publication number Publication date
CA2534120A1 (en) 2005-02-17
EP1651224B1 (en) 2011-10-05
WO2005013994A1 (en) 2005-02-17
ATE526967T1 (de) 2011-10-15
JP2007500676A (ja) 2007-01-18
EP1651224A1 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
US20090155185A1 (en) Medicaments for inhalation comprising an anticholinergic and a betamimetic
US7417051B2 (en) Medicaments comprising betamimetics and a novel anticholinergic
AU2007202303B2 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
US6608054B2 (en) Pharmaceutical compositions based on anticholinergics and endothelin antagonists
CA2440699C (en) Compounds for treating inflammatory diseases
CA2733294C (en) Pharmaceutical combination of a tiotropium salt and ciclesonide
US20040266869A1 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
US20020193392A1 (en) Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
AU2003232201B2 (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
US7851483B2 (en) Medicaments comprising steroids and a novel anticholinergic
CA2534120C (en) Medicaments for inhalation comprising anticholinergics and a betamimetic
US20110076238A1 (en) Compounds for the treatment of proliferative processes
US20040161386A1 (en) Pharmaceutical compositions based on anticholinergic and dopamine agonists
CA2481268C (en) Medicaments comprising steroids and a novel anticholinergic
US20020193394A1 (en) Compounds for treating inflammatory diseases
US20060239935A1 (en) Compositions for inhalation
CA2582207A1 (en) Inhalation medicament containing an anticholinesterase drug, salmeterol and a steroid selected from the ciclesonide or mometasone furoate group
CA2533791C (en) Medicaments for inhalation comprising betamimetics and an anticholinergic agent
AU2004262901A1 (en) Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
US20100015061A1 (en) Pharmaceutical Compositions Based on Anticholinergics and Andolast
EP1651230B1 (en) Medicaments for inhalation comprising steroids and a novel fluorene carboxylic acid ester
CA2582153A1 (en) Inhalation medicament containing a novel anticholinesterase drug, formoterol and a steroid
CA2430592C (en) New pharmaceutical compositions based on anticholinergics and dopamine agonists
CA2614631C (en) Pharmaceutical compositions based on anticholinergics and corticosteroids in the form of an inhalable solution or suspension
US20050042176A1 (en) Medicaments for inhalation comprising a novel anticholinergic and a steroid

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831